ArticleEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)2026
Cancer incidence and mortality trends from 2007 to 2021 in Milan.
Article in European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to evaluate long-term cancer incidence and mortality trends in the Italian provinces of Milan and Lodi (2007-2021), with a specific focus on the impact of the COVID-19 pandemic in 2020. Data from the Milan Cancer Registry, covering 3.5 million inhabitants, were analyzed. Cancer cases were classified using International Classification of Diseases-O-3 and mortality data with International Classification of Diseases-10 codes. The age-standardized rates were then computed. Joinpoint regression estimated trends excluding 2020 to avoid distortions, including sensitivity analyses. Quality indicators were preliminarily assessed. Overall, 335 849 cases were registered (173 058 males; 162 791 females). Incidence declined among males [annual percent change (APC) -1.9%/year, 2007-2021], driven by prostate, lung, colorectal, and bladder cancers. Female incidence showed heterogeneous patterns, stabilizing and modestly decreasing in recent years (APC -0.6%/year, 2011-2021). Mortality declined steadily in both sexes (-1.9%/year in males; -2.1%/year in females). In 2020, incidence rates dropped sharply compared with 2019 (-19% males; -13% females), reflecting diagnostic delays and competing mortality, but returned to baseline in 2021. Increases were limited to thyroid and testicular cancers, which are largely linked to differences in diagnostic intensity and exposure differences. Cancer incidence decreased among males and stabilized or slightly declined among females, while mortality continued to decrease in both sexes. The abrupt 2020 reduction reflects pandemic disruptions but has a limited long-term effect. These findings confirm the crucial role of population-based cancer registries in monitoring trends and supporting health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.